Phio Pharmaceuticals
PHIO
17 hedge funds and large institutions have $1.58M invested in Phio Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 5 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
51% more call options, than puts
Call options by funds: $724K | Put options by funds: $479K
21% more funds holding
Funds holding: 14 → 17 (+3)
18% more capital invested
Capital invested by funds: $1.34M → $1.58M (+$240K)
0.01% more ownership
Funds ownership: 0.03% → 0.05% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$351K |
| 2 |
BlackRock
New York
|
+$98.8K |
| 3 |
Two Sigma Investments
New York
|
+$95.6K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$65.6K |
| 5 |
Two Sigma Advisers
New York
|
+$64.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$355K |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$48K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$24.6K |
| 4 |
VFA
Valeo Financial Advisors
Carmel,
Indiana
|
-$11K |
| 5 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$6K |
PHIO Hedge Fund Activity: Q2 2021 in Review
17 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q2 2021, worth a combined $1.58M — up 18% from $1.34M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new PHIO positions and 5 closed out — a net gain of 3 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $351K. The largest seller was GSA Capital Partners, exiting entirely with an estimated $355K sold.
- 17 institutional investors held Phio Pharmaceuticals (PHIO) as of Q2 2021, up from 14 in Q1 2021.
- Funds reported $1.58M of Phio Pharmaceuticals stock for Q2 2021, up 18% quarter-over-quarter.
- 8 funds opened new Phio Pharmaceuticals positions in Q2 2021 and 5 closed out, a net change of +3 holders.
- The largest Phio Pharmaceuticals buyer in Q2 2021 was Vanguard Group, an estimated $351K added.
- The largest Phio Pharmaceuticals seller in Q2 2021 was GSA Capital Partners, an estimated $355K sold.
Based on aggregated 13F filings for Q2 2021.